← Eichor
Study identifier: NCT02836158 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

Condition: Primary Central Nervous System Lymphoma  ·  Sponsor: Navy General Hospital, Beijing

PhasePhase 2/Phase 3
Planned participants100
Who can joinAll sexes, 60 Years to 75 Years
Healthy volunteersNo

About this study

This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).

This description comes directly from the study's public registry record.

Talk to the study team

Liren Qian, M.D.  ·  +861066957676  ·  qlr2007@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Navy General HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02836158